Approximately 200 BRAF mutant alleles have been identified in human tumours. Activating
BRAF mutants cause feedback inhibition of GTP-bound RAS, are RAS-independent and …

Purpose Human epidermal growth factor receptor 2 (HER2, ERBB2)–activating mutations
occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a …

The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …

An association between cancer and thrombosis has been recognized for more than a
century. However, the manner by which tumor growth is regulated by coagulation in vivo …

The role of KRAS, when activated through canonical mutations, has been well established in
cancer. Here we explore a secondary means of KRAS activation in cancer: focal high-level …

Biological therapies such as tumor necrosis factor-α inhibitors have advanced the treatment
of rheumatoid arthritis, but one-third of patients do not respond to such therapy. Furthermore …

The principles that govern the evolution of tumors exposed to targeted therapy are poorly
understood. Here we modeled the selection and propagation of an amplification in the BRAF …

Background Desmoid tumours are locally aggressive tumours associated with substantial
morbidity. No systemic treatments are approved for this disease, with methotrexate …

ENMD-2076 is a novel orally active, small molecule kinase inhibitor with a mechanism of
action involving several pathways key to tumor growth and survival: angiogenesis …

[Frontiers in Bioscience 6, d1403-1411, November 1, 2001] 1403 CYTOKERATIN 8
FUNCTIONS AS A MAJOR PLASMINOGEN RECEPTOR IN SELECT Page 1 [Frontiers in …